Grail (GRAL) | Stock Overview & Key Data
Grail Performance Comparison
Stock Range
Today's Range
Low: $31.00
High: $33.25
on August 21, 2025
52 Week Range
Low: $12.33
High: $63.99
on October 7, 2024
on February 18, 2025
All-Time High: $63.99 on February 17, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.1B
EPS
-11.71
P/E Ratio (TTM)
-0.49
Forward P/E
-2.78
P/B Ratio
0.49
PEG Ratio
0.01
Div. Yield
N/A
ROE
-17.68%
Beta
N/A
Debt to Equity
2.69
Financial Highlights
Profitability
Gross Margin
-50.01%
Operating Margin
-368.15%
Profit Margin
-62.12%
Returns and Earnings
Return on Assets (TTM)
-11.81%
Return on Equity (TTM)
-17.68%
EBITDA
$810.8M
Net Income (TTM)
$-443.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$3.96
Quarterly Revenue Growth (YoY)
11.20%
Quarterly Earnings Growth (YoY)
11.18%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Grail GRAL | 1.13B Small-cap | 3.01% | -3.49% | -11.51% | -18.61% | 84.99% | 115.12% | 126.74% | 126.74% |
| Thermo Fisher TMO | 184.10B Large-cap | -0.26% | 19.46% | 21.46% | -9.16% | -7.43% | -20.19% | -14.18% | 13.97% |
| Danaher DHR | 151.04B Large-cap | -3.01% | 8.42% | 9.15% | -3.01% | -11.27% | -24.34% | -17.95% | 11.85% |
| Twist Bioscience TWST | 1.69B Small-cap | -8.22% | -23.87% | -7.02% | -35.92% | -41.58% | -39.37% | -38.58% | -61.61% |
| Neogen NEOG | 1.22B Small-cap | 1.82% | 17.15% | -9.97% | -44.22% | -53.10% | -66.63% | -73.62% | -85.24% |
| Opko Health OPK | 1.09B Small-cap | 2.22% | -1.43% | 6.15% | -17.86% | -4.83% | -14.29% | -40.26% | -58.68% |
Ownership & Short Interest
Insider Ownership
13.83%
Institutional Ownership
73.41%
Shares Short
5M
Short Ratio
4.38
Short % of Shares Outstanding
15.40%
Average 10-Day Volume
934K
Average 90-Day Volume
971K
Grail Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Grail would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is GRAL's 52-week high and low?
- In the last 52 weeks, Grail reached a high of $63.99 (on February 18, 2025) and a low of $12.33 (on October 7, 2024).
- What is the market cap and P/E ratio for GRAL?
- Curious about Grail's size and valuation? Its market capitalization stands at 1.13B. When it comes to valuation, the P/E ratio (trailing twelve months) is -0.49, and the forward P/E (looking ahead) is -2.78.
- Does GRAL pay dividends? If so, what's the yield?
- As for dividends, Grail isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Grail's main competitors or similar companies to consider before investing?
When looking at Grail, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO184.10B Healthcare Diagnostics & Research -20.19% -14.18% Danaher
DHR151.04B Healthcare Diagnostics & Research -24.34% -17.95% Twist Bioscience
TWST1.69B Healthcare Diagnostics & Research -39.37% -38.58% Neogen
NEOG1.22B Healthcare Diagnostics & Research -66.63% -73.62% Opko Health
OPK1.09B Healthcare Diagnostics & Research -14.29% -40.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Grail Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Grail's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -17.68%, the Debt to Equity ratio from the most recent quarter is 2.69, and its Gross Profit Margin stands at -50.01%.
- What is the recent revenue and earnings growth for GRAL?
- Looking at Grail's growth, its revenue over the trailing twelve months (TTM) was $134M. Compared to the same quarter last year (YoY), quarterly revenue grew by 11.20%, and quarterly earnings saw a YoY growth of 11.18%.
- How much of GRAL stock is held by insiders and institutions?
- Wondering who owns Grail stock? Company insiders (like executives and directors) hold about 13.83% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 73.41%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.